GlaxoSmithKline has a total of 14306 patents globally, out of which 4376 have been granted. Of these 14306 patents, more than 70% patents are active. United States of America is where GlaxoSmithKline has filed the maximum number of patents, followed by Europe and Japan and it also seems reasonable as the biggest market for GlaxoSmithKline is USA & Europe. Parallelly, USA & Europe seems to be the main focused R&D center and United Kingdom is the origin country of GlaxoSmithKline.
GlaxoSmithKline was founded in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham. The company doing business in Pharmaceuticals, Biotechnology and Consumer goods Industry. The Company offers a wide range of products in Pharmaceutical and Consumer healthcare. As of December 2021, GlaxoSmithKline has a market cap of $107.37 Billion.
Do read about some of the most popular patents of GlaxoSmithKline which have been covered by us in this article and also you can find GlaxoSmithKline patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over GlaxoSmithKline patent portfolio.
How many patents does GlaxoSmithKline have?
GlaxoSmithKline has a total of 14306 patents globally. These patents belong to 2162 unique patent families. Out of 14306 patents, 9982 patents are active.
How many GlaxoSmithKline patents are Alive/Dead?
Worldwide Patents
How Many Patents did GlaxoSmithKline File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | GSK Applications Filed | GSK Patents Granted |
| 2011 | 1521 | – |
| 2012 | 1985 | 9 |
| 2013 | 1582 | 49 |
| 2014 | 1619 | 227 |
| 2015 | 1664 | 351 |
| 2016 | 1653 | 582 |
| 2017 | 1483 | 712 |
| 2018 | 1356 | 680 |
| 2019 | 764 | 696 |
| 2020 | 431 | 587 |
| 2021 | 129 | 483 |
Which GlaxoSmithKline Drug Patents are Expiring in the Next 10 Years?
The patent no. US8113199B2 which is expiring in Oct, 2027, describing a helpful dose counter is designed to minimize false counts and tampering risks. It consists of a rotating index wheel with recesses and an indexer that accurately counts and tracks individual medicine doses on the carrier.
Given below is the list of few drugs patented by GlaxoSmithKline accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.
| Drug Name | Patent Number | Patent Title | Patent Expiration |
| Breo Ellipta | US8113199B2 | Counter For Use With A Medicament… | Oct, 2027 |
| Zejula | US11673877B2 | Niraparib Compositions | Mar, 2038 |
| Jesduvroq | US8557834B2 | Prolyl Hydroxylase Inhibitors | Jun, 2027 |
| Nicorette | US8501164B2 | Nicotine Lozenge Compositions | Jun, 2029 |
| Lamictal Odt | US7919115B2 | Orally Disintegrating Tablet… | Jan, 2029 |
Interested in knowing about GlaxoSmithKline’s Drug Patents Expiring in the next 10 years?
How Many Patents did GlaxoSmithKline File in Different Countries?
Countries in which GlaxoSmithKline Filed Patents
| Country | Patents |
| United States Of America | 1641 |
| Europe | 1219 |
| Japan | 989 |
| China | 786 |
| Canada | 777 |
| Australia | 746 |
| Brazil | 603 |
| Korea (South) | 518 |
| United Kingdom | 351 |
| Spain | 341 |
| Singapore | 310 |
| Mexico | 308 |
| Israel | 303 |
| Russian Federation | 279 |
| Taiwan | 234 |
| Eurasian Patent Organization | 223 |
| Argentina | 210 |
| Peru | 167 |
| India | 159 |
| South Africa | 154 |
| Chile | 152 |
| Hong Kong (S.A.R.) | 141 |
| Philippines | 128 |
| Thailand | 127 |
| Portugal | 126 |
| Denmark | 119 |
| Morocco | 119 |
| Uruguay | 118 |
| Poland | 118 |
| Costa Rica | 116 |
| Dominican Republic | 108 |
| Colombia | 106 |
| Croatia | 103 |
| Hungary | 100 |
| Slovenia | 100 |
| Lithuania | 91 |
| Belgium | 88 |
| New Zealand | 75 |
| Serbia | 75 |
| Cyprus | 61 |
| Ukraine | 52 |
| Viet Nam | 51 |
| Indonesia | 48 |
| Turkey | 40 |
| Montenegro | 38 |
| Malaysia | 32 |
| San Marino | 18 |
| Jordan | 18 |
| Germany | 12 |
| Norway | 11 |
| Ireland | 9 |
| Gulf Cooperation Council | 7 |
| Tunisia | 5 |
| African Regional Industrial Property Organization | 5 |
| Italy | 4 |
| France | 4 |
| Saudi Arabia | 2 |
| Netherlands | 1 |
| Ecuador | 1 |
| Honduras | 1 |
| Guatemala | 1 |
| Republic of Moldova | 1 |
| Luxembourg | 1 |
| Nicaragua | 1 |
Where are Research Centers of GlaxoSmithKline Patents Located?
10 Best GlaxoSmithKline Patents
WO2011140324A1 is the most popular patent in the GlaxoSmithKline portfolio. It has received 232 citations so far from companies like Epizyme, Janssen Sciences Ireland, Novira Therapeutics and Pfizer.
Below is the list of 10 most cited patents of GlaxoSmithKline:
| Publication Number | Citation Count |
| WO2011140324A1 | 232 |
| WO2014179620A1 | 226 |
| WO2012006380A2 | 171 |
| WO2011140325A1 | 169 |
| WO2012005805A1 | 166 |
| WO2013029338A1 | 163 |
| WO2012158613A1 | 149 |
| WO2012163805A1 | 147 |
| WO2012006376A2 | 144 |
| WO2011161031A1 | 142 |
Which Companies are using GlaxoSmithKline Patents to Advance their Research?
If patents or patents from a particular technology area of a company receive a lot of citations, it implies that the technology is being followed and incrementally innovated by the citing companies. It also indicates that citing companies are working on similar and closely related technologies.
The top citing companies in the GlaxoSmithKline patent portfolio are IBM, Neurometrix and Modernatx Inc.
List of the top forward citing Companies –
| Company | Number of Patents |
| IBM | 9 |
| Neurometrix | 8 |
| Modernatx Inc | 7 |
| Ionis Pharmaceuticals | 7 |
| Janssen Pharmaceuticals | 7 |
| Roche Innovation Center | 6 |
| Bristol-Myers Squibb | 4 |
| Genentech | 4 |
| Pfizer | 3 |
| Biopharma Credit | 3 |
Count of 102 and 103 Type Rejections based on GlaxoSmithKline Patents
Top GlaxoSmithKline Patents used in Rejecting Most Patent Applications
| Patent Number | Count of Rejected Applications |
| US9127276B2 | 11 |
| US20130118255A1 | 9 |
| US20110215931A1 | 9 |
| US8948876B2 | 8 |
| US8853408B2 | 7 |
| US10279179B2 | 6 |
| US8642752B2 | 6 |
| US9181549B2 | 5 |
| US9740549B2 | 5 |
| US20140193517A1 | 5 |
| US9827420B2 | 5 |
| US20110218756A1 | 4 |
| US9295646B2 | 4 |
| US20130192356A1 | 4 |
| US10286037B2 | 4 |
What Percentage of GlaxoSmithKline US Patent Applications were Granted?
GlaxoSmithKline (Excluding its subsidiaries) has filed 2285 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 1443 have been granted leading to a grant rate of 68.0%.
Below are the key stats of GlaxoSmithKline patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for GlaxoSmithKline?
| Law Firm | Total Applications | Success Rate |
| Glaxosmithkline | 1570 | 66.28% |
| Novartis Pharmaceutical Corporation | 136 | 37.62% |
| Birch Stewart Kolasch & Birch | 59 | 74.36% |
| Morrison & Foerster | 45 | 56.82% |
| Mccarter & English | 29 | 85.71% |
| Smithkline Beecham | 27 | 100.00% |
| Foley & Lardner | 16 | 68.75% |
| Seed Intellectual Property Law Group | 16 | 78.57% |
| James M Kanagy | 15 | 100.00% |
| Mcdermott Will & Emery | 15 | 69.23% |
“We are a science-led global healthcare company with a special purpose to improve the quality of human life by helping people do more, feel better, live longer.”
GSK has made significant investments in scientific and technical expertise in order to develop and launch a pipeline of novel drugs that address the needs of patients, payers, and consumers. In the year 2020, GSK had invested £4.6 billion in R&D.
Each of GSK’s three businesses, which discover, develop, and manufacture revolutionary pharmaceutical medicines, vaccines, and consumer healthcare products, contributes to the company’s long-term priorities of Innovation, Performance, and Trust.
GSK’s approach to Pharmaceutical Research and Development (R&D) is driven by the multiplier impact of Science x Technology x Culture and focuses on immune system science, human genetics, and innovative technology. It will assist GSK in speeding up the development and delivery of transformative medicines by prioritising compounds with a higher chance of success and cancelling less promising programmes. It also allows the company to focus more on specialty medications, such as cancer.
GSK’s Vaccines division seeks to protect more people by expanding indications and delivering vaccines to new areas while balancing its focus on a solid pipeline with active life-cycle management of its existing vaccines. The company’s Innovation goal is to disrupt the vaccine discovery, development, and manufacturing processes in order to lead the industry. It will concentrate on advancing important assets in its pipeline and exploring novel technologies in order to capitalise on emerging fields’ potential. It is speeding the delivery of its most promising assets to meet the highest unmet medical need by leveraging its industry-leading science.
Oral Health, Pain Relief, Respiratory, Nutrition, Gastrointestinal and Skin Health are the five categories in which GSK’s Consumer Healthcare R&D group creates products. Its primary goal is to develop a robust, competitive pipeline of consumer-driven, science-based innovation.
EXCLUSIVE INSIGHTS COMING SOON
What are GlaxoSmithKline key innovation segments?
What Technologies are Covered by GlaxoSmithKline?
The chart below distributes patents filed by GSK in different countries on the basis of the technology protected in patents. It also represents the markets where GSK thinks it’s important to protect particular technology inventions
R&D Focus: How GlaxoSmithKline search focus changed over the years?
Interested in knowing about the areas of innovation that are being protected by GlaxoSmithKline?
EXCLUSIVE INSIGHTS COMING SOON
